152 related articles for article (PubMed ID: 11312370)
1. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.
Huang Y; Kong WP; Nabel GJ
J Virol; 2001 May; 75(10):4947-51. PubMed ID: 11312370
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
4. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.
Deml L; Bojak A; Steck S; Graf M; Wild J; Schirmbeck R; Wolf H; Wagner R
J Virol; 2001 Nov; 75(22):10991-1001. PubMed ID: 11602739
[TBL] [Abstract][Full Text] [Related]
5. Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine.
Akahata W; Yang ZY; Nabel GJ
J Virol; 2005 Jan; 79(1):626-31. PubMed ID: 15596858
[TBL] [Abstract][Full Text] [Related]
6. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
7. Induction of HIV-specific T and B cell responses with a replicating and conditionally infectious lentiviral vaccine.
Wingard JB; Anderson B; Weissman D
Eur J Immunol; 2008 May; 38(5):1310-20. PubMed ID: 18412164
[TBL] [Abstract][Full Text] [Related]
8. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.
Bolesta E; Gzyl J; Wierzbicki A; Kmieciak D; Kowalczyk A; Kaneko Y; Srinivasan A; Kozbor D
Virology; 2005 Feb; 332(2):467-79. PubMed ID: 15680412
[TBL] [Abstract][Full Text] [Related]
9. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
Wild J; Bojak A; Deml L; Wagner R
Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles.
Vajdy M; Gardner J; Neidleman J; Cuadra L; Greer C; Perri S; O'Hagan D; Polo JM
J Infect Dis; 2001 Dec; 184(12):1613-6. PubMed ID: 11740739
[TBL] [Abstract][Full Text] [Related]
11. [Construction of replication-deficient recombinant adenovirus expressing gag-polDelta and gp140TM genes of human immunodeficiency virus in mice].
Liu Y; Wu L; Zhou KM; Zhang XD; Hong KS; Shao YM
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Jun; 18(2):150-3. PubMed ID: 15340504
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
13. [Immunogenicities and comparison of DNA vaccines encoding pol genes derived from B`/C and A/E recombinant HIV-1 strains].
Wan YM; Ren YQ; Wang J; Ren XN; Hu ZD; Qiu C; Xu JQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Jun; 46(6):551-5. PubMed ID: 22943905
[TBL] [Abstract][Full Text] [Related]
14. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.
Kanekiyo M; Matsuo K; Hamatake M; Hamano T; Ohsu T; Matsumoto S; Yamada T; Yamazaki S; Hasegawa A; Yamamoto N; Honda M
J Virol; 2005 Jul; 79(14):8716-23. PubMed ID: 15994765
[TBL] [Abstract][Full Text] [Related]
15. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
16. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation.
Otten GR; Schaefer M; Doe B; Liu H; Megede JZ; Donnelly J; Rabussay D; Barnett S; Ulmer JB
Vaccine; 2006 May; 24(21):4503-9. PubMed ID: 16181711
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
[TBL] [Abstract][Full Text] [Related]
18. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
19. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
